Vero Beach, FL – According to filings with the U.S. Securities and Exchange Commission, Hdl Therapeutics is raising $50,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Matin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Hdl Therapeutics

We have developed the first therapy of its kind to rapidly reverse coronary atherosclerosis in patients with Homozygous Familial Hypercholesterolemia (HoFH). Our innovative acute care therapeutic device called PDS-2 System transforms a patient’s own plasma into an atherosclerostic reversal agent using our patented technology to allow for rapid regression of plaque in coronary arteries of patients with HoFH. We have a novel SAR-CoV-2 Viral Delipidation Therapy that is expected to create an enhanced immune response with a faster and more cost-effective method of development.

To learn more about Hdl Therapeutics, visit http://hdltherapeutics.com/

Contact:
Michael Matin, Chief Executive Officer
772-453-2770
michael.matin@hdltherapeutics.com
https://www.linkedin.com/in/michaelmatin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved